Clinical Ovarian Cancer RSS feed: Articles in Press. Clinical Ovarian Cancer is a peer-reviewed, semi-annual journal that publishes original articles describing various aspects of clinical and translational research in ovarian cancer. Clinical Ovarian Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of ovarian and other gynecologic cancers. The main emphasis is on recent scientifi c developments in all areas related to gynecologic malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches. http://www.clinical-ovarian-cancer.com//inpress?rss=yesElsevier Inc.en © 2012 Published by Elsevier Inc. Clinical Ovarian Cancer1941-43902012-05-21 © 2012 Published by Elsevier Inc. healthpermissions@elsevier.comhttp://www.clinical-ovarian-cancer.com/article/PIIS1941439012000219/abstract?rss=yes Micro-Abstract: New reliable biomarkers are needed for the development of more individualized treatment strategies in patients with ovarian cancer. The prognostic value of gene polymorphisms in the platelet-derived growth factor (PDGF) system were investigated in hypothesis-generating patient material followed by a validation in a second cohort. PDGF-AA 1589 G/T showed prognostic value in the first cohort but failed to demonstrate the same results in the validation study. Abstract: Introduction: New reliable and validated markers are desirable in the treatment of ovarian cancer. The platelet-derived growth factor (PDGF) system plays an important role in tumor growth and angiogenesis, and high expression of PDGF/PDGF receptor (PDGFR) has been reported in ovarian cancer. Single nucleotide polymorphisms (SNPs) within a gene may be important for the function of the protein. This had led to the hypothesis that SNPs within the PDGF system could have clinical relevance as prognostic biomarkers in ovarian cancer. Methods: The study included hypothesis-generating patient material from 170 patients with histologically verified epithelial ovarian cancer in which 5 tagging SNPs in the promoter region of the PDGF-AA, PDGF-BB, PDGFR-α, and PDGFR-β genes were analyzed by means of SNaPshot Multiplex (Applied Biosystems, Carlsbad, CA) and sequencing methods. The results were validated in an independent second cohort of 85 patients. Results: In the hypothesis-generating study, survival analyses were made for all 5 SNPs. PDGF-AA 1589 G/T genotype was found to be associated with overall survival in univariate analysis (P = .03), with a clear trend seen in Cox multivariate analysis (P = .12; hazard ratio, 0.75). However, the suggested prognostic importance of PDGF-AA 1589 G/T was not confirmed in the second cohort. Conclusion: Tagging SNPs in the promoter region of the PDGF-AA, PDGF-BB, PDGFR-α, and PDGFR-β genes, as evaluated here, are not likely to be of prognostic importance in patients with ovarian cancer. Platelet-Derived Growth Factor Gene Polymorphisms in Patients with Ovarian Cancer - Corrected ProofChristine Vestergaard Madsen, Karina Dahl Steffensen, Marianne Waldstrøm, Rikke Fredslund Andersen, Charlotte Hasselholt Søgaard, Ivan Brandslund, Anders Jakobsen10.1016/j.cloc.2012.02.020Clinical Ovarian Cancer (2012)2012-05-21Clinical Ovarian Cancer2012-05-21ORIGINAL STUDYhttp://www.clinical-ovarian-cancer.com/article/PIIS1941439011000341/abstract?rss=yesUnusual Collision Tumor of Ovary: Endometrioid Adenocarcinoma and Teratoma - Corrected ProofEliyaz Ahmed, Shatrughan P. Sah, Anilkumar Adikesavalu, Krishnaswamy Madhavan, Khalil Razvi10.1016/j.cloc.2011.12.001Clinical Ovarian Cancer (2012)2012-02-02Clinical Ovarian Cancer2012-02-02CASE REPORThttp://www.clinical-ovarian-cancer.com/article/PIIS194143901100033X/abstract?rss=yesMicro-Abstract: Women with advanced ovarian cancer benefit from the addition of intraperitoneal (IP) chemotherapy after optimal cytoreductive surgery. Due to catheter complications, many patients are unable to complete IP chemotherapy. This study looks at a new technique for inserting IP catheters. 38 patients charts were retrospectively reviewed, two catheter complications were identified: a “flipped” reservoir, and an infection at the port site. This technique successfully eliminated major catheter complications.Abstract: Background: Ovarian cancer is the leading cause of death from gynecologic malignancies in the United States. The NCI released a clinical announcement supporting the use of intraperitoneal chemotherapy in addition to intravenous chemotherapy. However, multiple trials have shown that IP administration is severely limited by catheter complications.Purpose: We present a new technique for inserting and securing IP catheters in order to prevent the previously reported complications, in particular obstruction of the catheter, bowel and vaginal cuff perforation.Methods: From March 2006 through February 2010, 38 patients with stage III or IV ovarian cancer underwent optimal cytoreductive surgery and had an IP catheter placed via the “Hammock” technique.Results: 14 patients underwent modified posterior exenteration (37%); 6 underwent splenectomy (16%); thirteen small bowel resections (34%). All 38 patients underwent pelvic and aortic lymphadenectomy. Two patients had reservoir complications; one “flipped over”, and the other had an infection at the port site. Both patient’s elected to discontinue the IP portion of the chemotherapy regimen. 219 cycles of chemotherapy were completed (96%) out of a possible 228 cycles. The only complications were related to the reservoir. There were no catheter-related complications.Conclusion: As an increasing number of IP catheters are placed at the time of cytoreductive surgery, we will continue to have catheter complications and IP chemotherapy administration difficulties. In using the “Hammock” Technique, we had no catheter complications, and a 96% chemotherapy completion rate. We recommend using the “Hammock” Technique for inserting and securing IP catheters at the time of cytoreductive surgery. .Intraperitoneal Catheter Placement: The “Hammock” Technique - Corrected ProofChristina L. Kushnir, Aimee C. Fleury, David F. Silver, Nick M. Spirtos10.1016/j.cloc.2011.08.001Clinical Ovarian Cancer (2011)2011-10-24Clinical Ovarian Cancer2011-10-24ORIGINAL STUDY